SLC5A2 and hydrops fetalis: Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for HF (OR 0.52; 95% CI [0.42, 0.65]; I2 = 0%; certainty: high) and improved KCCQ scores, which were measured 4 months after treatment in the SOLOIST-WHF trial and 90 days after treatment in the EMPUSLE trial (mean difference 4.12; 95% CI [0.1.89, 6.53]; I2 = 0%; certainty: high; Fig. 3).